Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

(Carlsbad, CA, USA) have entered into a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. By running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system, researchers will be able to detect the pTau217 signal in less invasive sample collection types, such as plasma samples, in just 90 minutes without any manual intervention, improving efficiency, scalability, and precision while providing the required information to help accelerate clinical decisions.

"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."

"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."

Related Links:
Bio-Techne Corporation
ALZpath, Inc.